The Importance of Nonpharmacological Applications in the Management of Infections Caused by Stenotrophomonas maltophilia in Pediatric Patients: A Single-Center Experience

Abstract

Objective This study aimed to contribute to the literature by evaluating the clinical characteristics of children with Stenotrophomonas maltophilia infection, predisposing factors, and implementation of additional measures for disease control, with the goal of improving survival and reducing mortality in pediatric patients.

Methods Clinical data and microbiological test results of patients with S. maltophilia growth in cultures of samples from any biological site and clinical symptoms of systemic infection referred to the pediatric clinic of a tertiary university hospital between January 2021 and August 2023 were reviewed.

Results The study included 40 patients with a median age of 2.5 years (range 1–16 years). Medical devices were present in 26 patients (65%). Polymicrobial growth occurred in 16 patients (40%). Prior to the detection of S. maltophilia infection, 35 patients (87.5%) received broad-spectrum antimicrobial therapy. Death occurred in 11 patients (27.5%). In 2022, there were 23 cases of S. maltophilia infection, with the highest number occurring in March 2022 (9 cases per month). After that date, various nonpharmacological measures were implemented for all patients with confirmed infection, including strict contact isolation in single-occupancy, high-efficiency particulate air-filtered rooms.

Conclusion There were multiple risk factors for increased mortality in our study population. Despite these unfavorable factors, the mortality rate was low. Disease control was achieved through nonpharmacological interventions implemented alongside antimicrobial therapy, resulting in effective prevention of potential outbreaks. Implementation of nonpharmacological interventions alongside medical treatment can reduce mortality and improve survival in pediatric patients with S. maltophilia infection.

Keywords

children - infection - Stenotrophomonas maltophilia

Ethical Approval

Ethical approval for this study was obtained from the Institutional Review Board of Gaziantep University (approval number 2023/264).

Consent to Participate

Informed consent was obtained from legal guardians to participate.

Consent for Publication

Informed consent was obtained from legal guardians for publication.

Publication History

Received: 14 November 2023

Accepted: 27 December 2023

Article published online:
22 April 2024

• References

• 1 Calza L, Manfredi R, Chiodo F. Stenotrophomonas (Xanthomonas) maltophilia as an emerging opportunistic pathogen in association with HIV infection: a 10-year surveillance study. Infection 2003; 31 (03) 155-161
• 2 Falagas ME, Kastoris AC, Vouloumanou EK, Dimopoulos G. Community-acquired Stenotrophomonas maltophilia infections: a systematic review. Eur J Clin Microbiol Infect Dis 2009; 28 (07) 719-730
• 3 Brooke JS. Advances in the microbiology of Stenotrophomonas maltophilia . Clin Microbiol Rev 2021; 34 (03) e0003019
• 4 Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 2012; 25 (01) 2-41
• 5 Paez JI, Tengan FM, Barone AA, Levin AS, Costa SF. Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 2008; 27 (10) 901-906
• 6 Falagas ME, Kastoris AC, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, Dimopoulos G. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol 2009; 4 (09) 1103-1109
• 7 Paez JI, Costa SF. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect 2008; 70 (02) 101-108
• 8 Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the treatment of AmpC β-lactamase-producing enterobacterales, carbapenem-resistant acinetobacter baumannii, and stenotrophomonas maltophilia infections. Clin Infect Dis 2022; 74 (12) 2089-2114
• 9 Sumida K, Chong Y, Miyake N. et al. Risk factors associated with Stenotrophomonas maltophilia bacteremia: a matched case-control study. PLoS One 2015; 10 (07) e0133731
• 10 Wang CH, Lin JC, Lin HA. et al. Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: a 10-year retrospective study. J Microbiol Immunol Infect 2016; 49 (03) 378-386
• 11 Ebara H, Hagiya H, Haruki Y, Kondo E, Otsuka F. Clinical characteristics of Stenotrophomonas maltophilia bacteremia: a regional report and a review of a Japanese case series. Intern Med 2017; 56 (02) 137-142
• 12 Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36 (05) 309-332
• 13 Kalil AC, Metersky ML, Klompas M. et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63 (05) e61-e111
• 14 Subcommittee on Urinary Tract Infection. Reaffirmation of AAP Clinical Practice Guideline: the diagnosis and management of the initial urinary tract infection in febrile infants and young children 2-24 months of age. Pediatrics 2016; 138 (06) e20163026
• 15 Arthur C, Tang X, Romero JR, Gossett JG, Harik N, Prodhan P. Stenotrophomonas maltophilia infection among young children in a cardiac intensive care unit: a single institution experience. Pediatr Cardiol 2015; 36 (03) 509-515
• 16 Büyükcam A, Bıçakcıgil A, Cengiz AB, Sancak B, Ceyhan M, Kara A. Stenotrophomonas maltophilia bacteremia in children - a 10-year analysis [in Spanish]. Arch Argent Pediatr 2020; 118 (03) e317-e323
• 17 Tokatly Latzer I, Paret G, Rubinstein M, Keller N, Barkai G, Pessach IM. Management of Stenotrophomonas maltophilia infections in critically ill children. Pediatr Infect Dis J 2018; 37 (10) 981-986
• 18 Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol 2015; 6: 893
• 19 Lai CH, Wong WW, Chin C. et al. Central venous catheter-related Stenotrophomonas maltophilia bacteraemia and associated relapsing bacteraemia in haematology and oncology patients. Clin Microbiol Infect 2006; 12 (10) 986-991
• 20 Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, Duin DV, Clancy CJ. Infectious Diseases Society of America 2023 (IDSA). Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0. Accessed August 29, 2023 at: https://www.idsociety.org/practice-guideline/amr-guidance-2.0/
• 21 Pathmanathan A, Waterer GW. Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection. Eur Respir J 2005; 25 (05) 911-914
• 22 Abbas AA, Fryer CJ, Felimban SK, Yousef AA, Fayea NY, Osoba O. Stenotrophomonas maltophilia infection related mortality during induction in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 2003; 41 (01) 93-94
• 23 Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 2002; 45 (01) 47-53
• 24 Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 2003; 22 (06) 551-556
• 25 Lanotte P, Cantagrel S, Mereghetti L. et al. Spread of Stenotrophomonas maltophilia colonization in a pediatric intensive care unit detected by monitoring tracheal bacterial carriage and molecular typing. Clin Microbiol Infect 2003; 9 (11) 1142-1147
• 26 Micozzi A, Venditti M, Monaco M. et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis 2000; 31 (03) 705-711
• 27 Mutlu M, Yılmaz G, Aslan Y, Bayramoğlu G. Risk factors and clinical characteristics of Stenotrophomonas maltophilia infections in neonates. J Microbiol Immunol Infect 2011; 44 (06) 467-472
• 28 Nseir S, Di Pompeo C, Brisson H. et al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care 2006; 10 (05) R143
• 29 Alsuhaibani M, Aljarbou A, Althawadi S, Alsweed A, Al-Hajjar S. Stenotrophomonas maltophilia bacteremia in children: risk factors and mortality rate. Antimicrob Resist Infect Control 2021; 10 (01) 19